NSCLC HER2 Alterations Testing

CME

Medical Minute 1: HER2 Alterations and Testing in NSCLC

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Released: October 17, 2024

Expiration: April 16, 2025

Misako Nagasaka
Misako Nagasaka, MD, PhD

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Which of the following most accurately describes the relative incidence of brain metastases in patients with HER2-mutated NSCLC compared with patients with EGFR- or KRAS-mutated NSCLC?

2.

Which of the following most accurately describes the current FDA approval for trastuzumab deruxtecan for patients with advanced NSCLC?